Portfolio Exits
1Partners & Customers
10About Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma (TYO: 4508) is a research-driven pharmaceutical company based in Japan, specializing in research, development, and marketing of globally competitive pharmaceutical products focused on the field of autoimmune disease, diabetes and kidney disease, and CNS disease.
Mitsubishi Tanabe Pharma Headquarter Location
3-2-10, Dosho-machi Chuo-ku
Osaka, 541-8505,
Japan
+81-6-6205-5085
Expert Collections containing Mitsubishi Tanabe Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Mitsubishi Tanabe Pharma in 1 Expert Collection, including Diabetes.
Diabetes
1,750 items
Latest Mitsubishi Tanabe Pharma News
May 13, 2022
The US Food and Drug Administration has approved Radicava ORS (edaravone) oral suspension for the treatment of adults with amyotrophic lateral sclerosis (ALS). Developed by Japanese drugmaker Mitsubishi Tanabe Pharma, a part of Mitsubishi Chemical (TYO: 4188), Radicava ORS is an orally administered version of Radicava, which was originally approved in 2017 as an intravenous (IV) infusion to treat ALS, commonly referred to as Lou Gehrig’s… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login . If your trial has come to an end, you can subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK
Mitsubishi Tanabe Pharma Portfolio Exits
1 Portfolio Exit
Mitsubishi Tanabe Pharma has 1 portfolio exit. Their latest portfolio exit was Green Cross Pharmaceutical on .
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
Divestiture | 1 |
Date | |
|---|---|
Exit | Divestiture |
Companies | |
Valuation | |
Acquirer | |
Sources | 1 |
Mitsubishi Tanabe Pharma Acquisitions
2 Acquisitions
Mitsubishi Tanabe Pharma acquired 2 companies. Their latest acquisition was NeuroDerm on October 18, 2017.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
10/18/2017 | Other | $20.5M | Acq - P2P | 11 | ||
9/18/2013 | Other Venture Capital |
Date | 10/18/2017 | 9/18/2013 |
|---|---|---|
Investment Stage | Other | Other Venture Capital |
Companies | ||
Valuation | ||
Total Funding | $20.5M | |
Note | Acq - P2P | |
Sources | 11 |
Mitsubishi Tanabe Pharma Partners & Customers
10 Partners and customers
Mitsubishi Tanabe Pharma has 10 strategic partners and customers. Mitsubishi Tanabe Pharma recently partnered with HitGen on February 2, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
2/25/2022 | Partner | China | In December 2018 , HitGen Inc. and MTPC entered into a drug discovery research collaboration to identify novel small molecule hits for multiple targets of interest . | 3 | |
10/25/2021 | Licensor | United States | In Europe , Russia and Turkey , Janssen Biotech , Inc. licenses distribution rights to REMICADE to Schering-Plough Company , a subsidiary of Merck & Co , Inc. . | 1 | |
11/5/2020 | Licensor | United States | In Japan , Indonesia , and Taiwan , Janssen licenses distribution rights to REMICADE to Mitsubishi Tanabe Pharma Corporation . | 1 | |
8/18/2020 | Partner | ||||
4/8/2020 | Licensor |
Date | 2/25/2022 | 10/25/2021 | 11/5/2020 | 8/18/2020 | 4/8/2020 |
|---|---|---|---|---|---|
Type | Partner | Licensor | Licensor | Partner | Licensor |
Business Partner | |||||
Country | China | United States | United States | ||
News Snippet | In December 2018 , HitGen Inc. and MTPC entered into a drug discovery research collaboration to identify novel small molecule hits for multiple targets of interest . | In Europe , Russia and Turkey , Janssen Biotech , Inc. licenses distribution rights to REMICADE to Schering-Plough Company , a subsidiary of Merck & Co , Inc. . | In Japan , Indonesia , and Taiwan , Janssen licenses distribution rights to REMICADE to Mitsubishi Tanabe Pharma Corporation . | ||
Sources | 3 | 1 | 1 |
Mitsubishi Tanabe Pharma Team
2 Team Members
Mitsubishi Tanabe Pharma has 2 team members, including current President, Michihiro Tsuchiya.
Name | Work History | Title | Status |
|---|---|---|---|
Michihiro Tsuchiya | President | Current | |
Natsuki Hayama | President | Former |
Name | Michihiro Tsuchiya | Natsuki Hayama |
|---|---|---|
Work History | ||
Title | President | President |
Status | Current | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.